| |
|
|
Effects of cannabinoids on cholinergic-mediated contraction of human bronchi
UPRES EA220
The current study was performed to investigate the role of cannabinoid (CB) receptors on the cholinergic contraction of isolated human airways. Results obtained with WIN55,212-2 (CB1/CB2 agonist), JWH-133 (CB2 agonist) and CB receptor selective antagonists suggest that CB1-receptor stimulation inhibits the cholinergic contraction in human isolated bronchi through stimulation of prejunctional receptors, located to post-ganglionic cholinergic nerves.
|
Accuwik® Ultra Membrane for the Direct Collection, Storage, and Efficient Rapid Release of Biological Samples for Clinical Diagnostics
Pall Life Sciences
Poster data assesses use of Pall’s Accuwik Ultra membrane as a reliable tool for direct collection of clinical samples including saliva and plasma, enables stability during sample storage, and allows for rapid and efficient release of clinically relevant protein biomarkers suitable for diagnostic analyses.
|
Expression of stress response protein GRP78 is associated with the development of castration-resistant prostate cancer
University of Southern California, Los Angeles, California, USA
This study investigated the role of the GRP78 in prostate cancer progression and the development of castration-resistant prostate cancer, where cancer cells continue to survive despite the stress of an androgen-starved environment.
|
|
|
|
|
|
Permanent Senior Scientist Position in NMR-based Metabolomics
CIBERDEM
Tarragona, Spain
|
|
|
BBSRC Funded Microfluidics Engineering Resarch PhD
University College London
London, UK
|
|
|
Post-Doctpral Position in Mollusk Health Laboratory
UPEI
Charlottetown, Canada
|
|
|
Production Chemist II
Independent
Torrance, CA, USA
|
|
|
Research Chemist
Independent
Torrance, CA, USA
|
|
|
QC Analyst
Genomic Health
Redwood City, CA, USA
|
|
|
Research Scientist II - Biology
Gilead Sciences
Foster City, CA, USA
|
|
|
Assistant Director, Automation Services
Medarex, Inc.
Milpitas, CA, USA
|
|
|
|
InfoTech for Pharma & Biotech, Basel, Switzerland
20 May 2008 - 21 May 2008
Generating new science from data: The application of (bio) informatics tools to turn information into knowledge.
For more information visit: http://www.iir-events.com/IIR-Conf/page.aspx?id=10965
Or email: Kye-ling.gan@informa.com
Please Quote your VIP code: CQ7037PMBA
|
Emerging Regulatory Issues in Genomic Medicine, Mexico City, Mexico
21 May 2008 - 23 May 2008
The purpose of this meeting is to identify synergies and common issues in Genomic Medicine and to develop common approaches to address these issues. The FDA has a major effort in the area of genomics and personalized medicine. It is working with clinicians, the pharmaceutical industry, and other regulatory agencies worldwide to integrate genomic medicine into medical practice
|
Personalised Medicine, London, UK
22 May 2008 - 23 May 2008
Optimising the efficiency of your R&D strategy through effective investment into the tailored and personalised medicine arena.
|
|
|
|
|
|
|
|
EGFR Mutation Detection and SNP Genotyping in 30 minutes; A Novel, New Molecular Diagnostic Technology
Paul Cizdziel, Senior Scientist, RIKEN Yokohama Institute, speaking at the Molecular Diagnostics World Congress 2007
|
|
A Simple Algorithm for Assessing Overall and Specific Impact of Diagnostic-Type Tests on Medicines Development and Marketing
Eddie Blair, Managing Director, Integrated Medicines, speaking at Molecular Diagnostics World Congress 2007
|
|
Microfluidic Approaches to Point-of-Care Diagnostics
Andrew deMello, Professor, Imperial College, speaking at the Lab-on-a-Chip World Congress 2007
|
|
|
|
Emerging Markets for Microfluidic Applications
Published May 2007
Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications.
|
Personalized Medicine Market Report 2007
Published April 2007
This report presents the latest industry analysis of the emerging field of Personalized Medicine. There is increasing interest in this field driven by the development of a number of molecular diagnostics-based tests that determine a patient’s genetic predisposition to a given disease—such as cancer, or to adverse drug reactions (ADRs).
|
|
|